Is Medicamen Biotec overvalued or undervalued?

As of 7 October 2025, Medicamen Biotec's valuation grade has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 42.42, an EV to EBITDA of 28.76, and a PEG ratio of 2.09, which suggest that while the company is not undervalued, it is also not excessively priced compared to its peers.
In comparison with notable peers, Sun Pharma has a PE ratio of 34.6 and an EV to EBITDA of 23.44, indicating it is considered expensive, while Cipla is rated attractive with a PE of 22.68. This positions Medicamen Biotec in a relatively stable valuation context within the pharmaceuticals and biotechnology sector. Despite a challenging recent performance against the Sensex, with a year-to-date return of -41.78% compared to the Sensex's 4.85%, the current valuation reflects a more balanced outlook for investors.